ATMP

Azzur Group Names Project Management Expert, Rob Chapman, Director of its Raleigh-Based Consulting Operation

Retrieved on: 
Wednesday, April 17, 2024

RALEIGH, N.C., April 17, 2024 /PRNewswire/ -- Azzur Group today announces the appointment of Rob Chapman to Director of Azzur Raleigh, Azzur Group's GxP advisory and consulting operation serving the burgeoning life science industry in the Southeastern U.S.

Key Points: 
  • RALEIGH, N.C., April 17, 2024 /PRNewswire/ -- Azzur Group today announces the appointment of Rob Chapman to Director of Azzur Raleigh, Azzur Group's GxP advisory and consulting operation serving the burgeoning life science industry in the Southeastern U.S.
  • Rob brings to Azzur Group more than 30 years of engineering and project management experience in the regulated pharmaceutical and life science space, with expertise in lean project management, process improvement, change and risk management, and project visualization.
  • "I am excited to embark on the next step of my career with Azzur Group," said Rob.
  • "We're grateful for the opportunity to welcome Rob to the Azzur Consulting team," said Allison Kerska , President, Azzur Consulting and Azzur Training Center.

Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee

Retrieved on: 
Wednesday, March 13, 2024

TAMPA, Fla., March 13, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to PCRX-201 (enekinragene inzadenovec), the company’s novel, intra-articular helper-dependent adenovirus (HDAd) gene therapy product candidate that codes for interleukin-1 receptor antagonist (IL-1Ra), for the treatment of osteoarthritis of the knee.

Key Points: 
  • PCRX-201 was well tolerated, with efficacy observed through at least 52 weeks at all doses and cohorts.
  • Preliminary 36-week data were presented at the Osteoarthritis Research Society International (OARSI) 2023 World Congress, the premier annual international forum in osteoarthritis research and treatment.
  • The 52-week data have been accepted for presentation at OARSI 2024 taking place in Vienna, Austria in April 2024 and the company expects to present 104-week efficacy and safety data later this year.
  • PCRX-201 was also granted Advanced Therapy Medicinal Products (ATMP) designation by the European Medicines Agency in May 2023.

YolTech Therapeutics to Participate in 2024 Cell & Gene Meeting on the Mediterranean

Retrieved on: 
Wednesday, March 27, 2024

SHANGHAI, March 27, 2024 /PRNewswire/ -- YolTech Therapeutics, a trailblazing biopharmaceutical company specializing in gene editing, is delighted to announce its participation in 2024 Cell & Gene Meeting on the Mediterranean.

Key Points: 
  • SHANGHAI, March 27, 2024 /PRNewswire/ -- YolTech Therapeutics, a trailblazing biopharmaceutical company specializing in gene editing, is delighted to announce its participation in 2024 Cell & Gene Meeting on the Mediterranean.
  • The Cell & Gene Meeting on the Mediterranean stands as the premier conference uniting the ATMP (Advanced Therapy Medicinal Products) community from Europe and beyond.
  • Join YolTech at 2024 Cell & Gene Meeting on the Mediterranean to explore the forefront of gene editing and witness firsthand the transformative potential it holds for the future of medicine.
  • For media inquiries or to schedule a meeting with YolTech Therapeutics' representatives at the event, please contact:

Global Advanced Therapy Medicinal Products CDMO Market Size, Share & Trends Analysis Report 2024 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 27, 2024

The "Global Advanced Therapy Medicinal Products CDMO Market Size, Share & Trends Analysis Report by Product (Gene Therapy, Cell Therapy), Phase, Indication, Region, and Segment Forecasts, 2024-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Advanced Therapy Medicinal Products CDMO Market Size, Share & Trends Analysis Report by Product (Gene Therapy, Cell Therapy), Phase, Indication, Region, and Segment Forecasts, 2024-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global advanced therapy medicinal products CDMO market is expected to reach USD 18.8 billion by 2030 and is expected to register a CAGR of 18.92% from 2024 to 2030, owing to rising clinical trials for advanced therapy medicinal products and the increasing awareness among researchers about the benefits of advanced therapies, driving the advanced therapy medicinal products (ATMP) CDMO market growth.
  • Similarly, gene and cell therapy are attracting a lot of patients for the treatment of rare diseases, whose incidence is rising globally.
  • In January 2020, the agency released six final guidelines on the manufacturing and clinical development of safe & efficient gene therapy products.

Compilation of quality review of documents (QRD) on stylistic matters in product information

Retrieved on: 
Sunday, March 10, 2024

29 February 2024

Key Points: 
    • 29 February 2024
      EMA/25090/2002 rev.23*
      Human Medicines Division

      Compilation of QRD decisions on stylistic matters in product information
      Issues
      Abbreviations

      Connected problems
      Subscript and superscript

      QRD Suggestions
      Acronyms must be written in their standard form; e.g.

    • Cmax, Cmax
      Abbreviations and

      Not always understood,

      Non-standard abbreviations and acronyms should be avoided, and the term should be written out in full.

    • The same applies when stating the pharmaceutical form in section 3 of the SmPC and section 4 of the labelling;
      i.e.
    • critical steps prior to administration of the product should also be included (section 5 of Annex IIIA).
    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 2/23

      Issues

      Connected problems

      QRD Suggestions

      emphasise in the labelling
      the special handling prior
      to administration of the
      product.

    • Consistency

      Inconsistencies in style are

      Once a particular style or house style has been selected, it must be used consistently throughout the text.

    • Tradename 150 mg solution for injection in pre-filled syringe
      Tradename 150 mg solution for injection in pre-filled pen

      information annexes?

    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 3/23

      Issues
      Desiccant

      Connected problems

      QRD Suggestions

      For medicinal products

      The foil of blister packs containing a desiccant must be clearly labelled to show which blister pocket contains

      packaged with a desiccant

      the desiccant.

    • For bottles containing a desiccant, a similar statement should also be considered provided there

      mistake the desiccant for a

      is available space.

    • It can only be included in brackets in section 3 of the

      where can this be

      SmPC and section 4 of the labelling.

    • Direct speech should only
      be used in section 6 of the SmPC for instructions about shelf-life, storage, handling and disposal.
    • The term ?drug? though can be used in the product information annexes when it is part of a standard set of
      terms (e.g.
    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 5/23

      Issues
      Foreign terms

      Connected problems

      QRD Suggestions

      Foreign terms, particularly

      Foreign terms must be written in italics; e.g.

    • Patients can be referred to as ?he? or

      physician is often referred

      as ?she? when the medicinal product is exclusively for use by males or females.

    • if the product in question might be

      measurements are

      used by elderly patients), in brackets after the metric measures in the English text.

    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 6/23

      Issues

      Connected problems

      QRD Suggestions

      product name is composed
      of MAH+INN?

    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 7/23

      Issues

      Connected problems

      QRD Suggestions
      MT: English
      BG: Bulgarian
      NL: Dutch
      CZ: Czech or English at applicant?s discretion.

    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 14/23

      Issues

      Connected problems

      QRD Suggestions
      considered, e.g.

    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 16/23

      Issues
      Symbols: Non-Unicode

      Connected problems

      QRD Suggestions

      The use of non-Unicode

      Only Unicode symbols must be used in submitted product information annexes.

    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 20/23

      Issues

      Connected problems

      Units: SI base units -

      International Standard

      litre

      base units have been
      introduced in the European
      Union with Council
      Directive 80/181/EEC of
      20.12.79 (O.J.

    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 23/23

SmartCella obtains approval for GMP manufacturing and quality control testing of cell therapies

Retrieved on: 
Wednesday, February 7, 2024

STOCKHOLM, Feb. 7, 2024 /PRNewswire/ -- SmartCella, through its business unit ProCella, has been approved by the Swedish Medicinal Product Agency for manufacturing and quality control testing of sterile biological medicinal products for cell therapy.

Key Points: 
  • STOCKHOLM, Feb. 7, 2024 /PRNewswire/ -- SmartCella, through its business unit ProCella, has been approved by the Swedish Medicinal Product Agency for manufacturing and quality control testing of sterile biological medicinal products for cell therapy.
  • SmartCella is pleased to announce that ProCella has been granted manufacturing authorization as well as Good Manufacturing Practice (GMP) certification from the Swedish Medicinal Product Agency.
  • Niklas Prager, CEO of SmartCella, continues: "The approval of our GMP facility is a key milestone for SmartCella.
  • This, in combination with a stellar quality control system, makes us unique and we have a competitive advantage for future cell therapy product development.

Brenus Pharma, Winner of the Call for Proposals "Innovations in Biotherapies and Bioproduction for France 2030", Receives €5 Million for Its Anticancer Vaccine Immunotherapy

Retrieved on: 
Monday, January 22, 2024

Brenus Pharma announces the financing of nearly 5 million euros for its STC-1010 project as the winner of the " Innovations in Biotherapy and Bioproduction" call for proposals from France 2030 .

Key Points: 
  • Brenus Pharma announces the financing of nearly 5 million euros for its STC-1010 project as the winner of the " Innovations in Biotherapy and Bioproduction" call for proposals from France 2030 .
  • Brenus Pharma has developed the anti-cancer vaccine STC-1010, targeting metastatic colorectal cancer (mCRC), second leading cause of cancer mortality worldwide.
  • "Brenus Pharma stands out for its innovative platform that generates new cellular and vaccine immunotherapies guided by proteomics.
  • We thank the State via France 2030 for this support, which validates Brenus' technological approach and should accelerate its availability to patients," said Paul BRAVETTI , CEO of Brenus Pharma.

PDC*line Pharma and Partners Receive €8.1M From Walloon Region and Wallonia Health Cluster BioWin for Personalized Therapeutic Vaccine Project

Retrieved on: 
Wednesday, January 17, 2024

PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancer, announces today the selection of the PDC*neo+ project for funding by the Walloon region and BioWin, the health cluster for Wallonia.

Key Points: 
  • PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancer, announces today the selection of the PDC*neo+ project for funding by the Walloon region and BioWin, the health cluster for Wallonia.
  • Members of the project consortium will receive €8.1M ($8.9M) in funding, including €4.7M ($5.1M) for PDC*line Pharma.
  • View the full release here: https://www.businesswire.com/news/home/20240117630349/en/
    The project aims to develop PDC*neo+, a personalized therapeutic vaccine for colorectal cancer using PDC*line Pharma's innovative PDC*line technology.
  • Globally, colorectal cancer (CRC) is among the most prevalent and deadly cancers , with a high recurrence rate post-surgery and chemotherapy.

Human medicines European public assessment report (EPAR): Casgevy, Exagamglogene autotemcel, Status: Opinion

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Casgevy, Exagamglogene autotemcel, Status: Opinion

Key Points: 


Human medicines European public assessment report (EPAR): Casgevy, Exagamglogene autotemcel, Status: Opinion

Applied StemCell, Inc. Strengthens Executive Leadership with Two Key Appointments

Retrieved on: 
Monday, December 4, 2023

The recent acquisition of the company by QHP Capital in October has set the stage for an ambitious expansion focused on supporting cell manufacturing from development through commercialization.

Key Points: 
  • The recent acquisition of the company by QHP Capital in October has set the stage for an ambitious expansion focused on supporting cell manufacturing from development through commercialization.
  • George Hong joins Applied StemCell, Inc. as Chief Commercial Officer (CCO), bringing more than 20 years of experience in academic and industry roles within life sciences, serving as a sales, marketing, and commercial executive with increasing responsibilities.
  • Prior to joining Applied StemCell, Tim held key positions, including VP of Commercial Manufacturing at Adrian Biotech, VP of Manufacturing Science and Technology (MSAT) at RoslinCT, and over 8 years in commercial manufacturing and quality positions at Dendreon.
  • "We are thrilled to have George and Tim as valuable additions to the ASC leadership team," expressed Dr. Ruby Chen-Tsai, CEO of Applied StemCell.